DEVELOPMENT OF A SPIRAL LAMINAR FLOW INDUCING ENDOVASCULAR STENT FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE

Projektinformationen

SpiraStent

ID Finanzhilfevereinbarung: 650176

DOI 10.3030/650176

Abgeschlossenes Projekt

EK-Unterschriftsdatum 26 September 2014

Startdatum 1 Oktober 2014

Enddatum 28 Februar 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

VASCULAR FLOW TECHNOLOGIES LIMITED
United Kingdom

Ziel

The project is focused the medical device sector and specifically peripheral vascular (PV) devices. A large, unmet, and growing patient population will require treatment for Peripheral arterial disease (PAD) and revenue in this market will continue to grow driven by the aging population and the increased incidence of obesity and diabetes. Percutaneous transluminal angioplasty (PTA) is the most widely used non-surgical treatment, however when used in areas of long calcified stenosis, PTA does not show satisfactory results at long term follow up. Stenting has become the most obvious choice to overcome the limitations of PTA. Unfortunately, long term performance of stents appears to be problematic as they do not prevent (and may to a certain extent even cause) a failure mode known as restenosis. Whilst covered stents have tackled the problem of restenosis within the stent the stent itself interrupts the bloods natural spiral laminar flow (SLF) and increases laterally directed forces and wall shear stress downstream of the implantation causing downstream disease progression. Re-institution of the bloods SLF reduces the forces and turbulence caused by stenting, and reduces neointimal hyperplasia (NIH) distal to the stent which can lead to occlusion distal to the stent.

The global objective of the project is to develop an innovative endovascular stent that will reintroduce the natural spiral laminar flow both through the stent and distal to the stent that can be manufactured to be deployed using standard delivery system profiles. With the long term post project target of increasing patency rates to greater than 80% and reduce restenosis of the stent by greater than 20% and distal stenosis by greater than 20% at 2 year follow up.

As a result of the proposed project, we expect to improve our collective competitiveness and generate increased sales by capturing at least €25M p.a. of the European market for endovascular stents

Wissenschaftliches Gebiet

• engineering and technology › materials engineering › colors
• engineering and technology › materials engineering › coating and films
• social sciences › economics and business › business and management › employment
• medical and health sciences › clinical medicine › peripheral vascular disease
• natural sciences › physical sciences › acoustics › ultrasound

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

VASCULAR FLOW TECHNOLOGIES LIMITED

• Netto-EU-Beitrag: € 50 000,00
• Adresse: UNIT I PROSPECT BUSINESS CENTRE ; DD2 1TY Dundee ; Vereinigtes Königreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Scotland › Eastern Scotland › Angus and Dundee City
• Region: Scotland › Eastern Scotland › Angus and Dundee City
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00